Test result variation and the quality of evidence-based clinical guidelines

Clinica Chimica Acta

Volumn 346, Issue 1, 2004, Pages 19-24

  Fraser, Callum G ^a  

^a NHS TAYSIDE   (United Kingdom)

Author keywords

Biological variation; Cholesterol; CRP; Evidence based medicine; Imprecision

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL;

ACCURACY; ANALYTIC METHOD; CLINICAL LABORATORY; CONFERENCE PAPER; DECISION MAKING; EVIDENCE BASED MEDICINE; LABORATORY TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; SAMPLING;

C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMISTRY, CLINICAL; CHOLESTEROL; DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; GUIDELINES; HUMANS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY;

EID: 3242702506     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.12.032     Document Type: Conference Paper

References (16)

1. Price C.P., Christenson R.H. Evidence-based laboratory medicine: from principles to outcomes. 2003;AACC Press, Washington, DC
2. Fraser C.G. Biological variation: from principles to practice. 2001;AACC Press, Washington, DC
3. National Cholesterol Education Program Laboratory Standardization Panel Current status of blood cholesterol measurement in clinical laboratories in the United States. Clin. Chem. 34:1988;193-220
4. Ricos C., Alvarez V., Cava F., et al. Current databases on biologic variation: pros, cons and progress. Scand. J. Clin. Lab. Invest. 59:1999;491-500
5. Ricos C, Alvarez V, Cava F, et al. Biological variation database & desirable quality specifications. The 2001 update. http://www.westgard.com/ guest21.htm.
6. Fraser C.G., Hyltoft Petersen P. The importance of imprecision. Ann. Clin. Biochem. 28:1991;207-211
7. Fraser C.G. Optimum analytical performance for point of care testing. Clin. Chim. Acta. 307:2001;37-43
8. Fraser C.G., Hyltoft Petersen P., Libeer J.C., Ricos C. Proposals for setting generally applicable quality goals solely based on biology. Ann. Clin. Biochem. 34:1997;8-12
9. Scottish Intercollegiate Guidelines Network Lipids and the primary prevention of coronary heart disease. 1999;SIGN, Edinburgh
10. Pearson T.A., Mensah G.A., Alexander R.W., et al. AHA/CDC scientific statement. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 107:2003;499-511
11. Ledue T.B., Rifaia N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin. Chem. 49:2003;1258-1271
12. Franzini C. Need for correct estimates of biological variation: the example of C-reactive protein. Clin. Chem. Lab. Med. 36:1998;131-132
13. Macey E.M., Hayes T.E., Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin. Chem. 43:1997;52-58
14. Ockene I.S., Matthews C.E., Rifai N., Ridker P.M., Reed G., Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein assays in healthy adults. Clin. Chem. 48:2002;444-450
15. Campbell B., Flatman R., Badrick T., Kanowski D. Problem with high-sensitivity C-reactive protein (Letter). Clin. Chem. 49:2003;201
16. Campbell B., Badrick T., Flatman R., Kanowski D. Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann. Clin. Biochem. 39:2002;85-88